



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PH#9
RECEIVED

Applicants: Jennifer L. West and Brenda K. Mann

OCT 11 2002

TECH CENTER 1600/2900

Serial No.: 09/935,168

Art Unit: 1645

Filed: August 21, 2001

Examiner: Not Yet Assigned

For: *TISSUE ENGINEERING SCAFFOLDS PROMOTING MATRIX PROTEIN
PRODUCTION*

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit a Supplemental Information Disclosure Statement, including one (1) page of Form PTO-1449, copies of the eight (8) documents cited therein.

It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any fees to Deposit Account No. 50-1868.

Certification Under 37 C.F.R. §1.97 (e)(1)

Each item of information contained in this Supplemental Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Supplemental Information Disclosure Statement.

U.S.S.N.: 09/935,168
Filed: August 21, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

U.S. Patents

<u>Number</u>	<u>Issue Date</u>	<u>Patentee</u>	<u>Class/Subclass</u>
5,686,091	11-11-1997	Leong, et al.	424/426
5,916,585	06-29-1999	Cook, et al.	424/426
5,935,849	08-10-1999	Schinstine, et al.	435/325
6,017,301	01-25-2000	Schwartz, et al.	547/781
6,022,743	02-08-2000	Naughton, et al.	435/395
6,077,523	06-20-2000	Deghenghi	424/426

Foreign Documents

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 92/20371	11-26-1992	Celtrix Pharmaceuticals	PCT
WO 94/23740	10-27-1994	Celtrix Pharmaceuticals	PCT

U.S.S.N.: 09/935,168
Filed: August 21, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



Patrea L. Pabst
Reg. No. 31,284

Dated: October 4, 2002


HOLLAND & KNIGHT LLP
One Atlantic Center
1201 West Peachtree Street, N.E.
Suite 2000
Atlanta, Georgia 30309-3400
404-817-8473
FAX 404-817-8588
www.hklaw.com

U.S.S.N.: 09/935,168
Filed: August 21, 2001
SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

Certificate of Mailing under 37 CFR §1.8(a)

I hereby certify that this Supplemental Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: October 4, 2002


Erica C. Boughner

ATL1 #546967 v1



1645

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT CHECKLIST

Client and Matter Name: RICE 103

Client #/ Matter #: 077865/00001

Attorney and Due Date Pabst

Check Requested N/A

I have checked the following sources for references to be cited in the IDS and/ or
Supplemental IDS:

X Application and PTO Correspondence File

 Application

X IDS/ Supp. IDS

 Office Action/ PTO-892

 Other _____


X PCT File

X PCT Written Opinion

X International Search Report

 Other _____

Suggestions/Requests for other sources:


Erica C. Boughner

RECEIVED

OCT 11 2002

TECH CENTER 1600/2900

